Compare Cyfuse Biomedical KK with Similar Stocks
Dashboard
1
Poor Management Efficiency with a low ROE of 0%
- The company has reported losses. Due to this company has reported negative ROE
2
Poor long term growth as Operating profit has grown by an annual rate -371.81% of over the last 5 years
3
With a growth in Net Sales of 500.77%, the company declared Outstanding results in Dec 25
4
Risky - Negative EBITDA
5
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
JPY 6,659 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.87
-29.58%
2.33
Revenue and Profits:
Net Sales:
169 Million
(Quarterly Results - Dec 2025)
Net Profit:
-127 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
7.96%
0%
7.96%
6 Months
3.21%
0%
3.21%
1 Year
-36.79%
0%
-36.79%
2 Years
-16.89%
0%
-16.89%
3 Years
-46.07%
0%
-46.07%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%
Cyfuse Biomedical KK for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
33.40%
EBIT Growth (5y)
-371.81%
EBIT to Interest (avg)
-84.91
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.84
Sales to Capital Employed (avg)
0.02
Tax Ratio
0.31%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.23
EV to EBIT
-6.32
EV to EBITDA
-6.58
EV to Capital Employed
14.71
EV to Sales
84.36
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-232.72%
ROE (Latest)
-33.86%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY
Dec'25
Dec'24
Change(%)
Net Sales
169.00
28.10
501.42%
Operating Profit (PBDIT) excl Other Income
-128.60
-212.00
39.34%
Interest
5.30
2.60
103.85%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-126.70
-208.10
39.12%
Operating Profit Margin (Excl OI)
-817.50%
-7,865.90%
704.84%
USD in Million.
Net Sales
YoY Growth in quarter ended Dec 2025 is 501.42% vs -10.51% in Dec 2024
Consolidated Net Profit
YoY Growth in quarter ended Dec 2025 is 39.12% vs -281.14% in Dec 2024
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
231.00
54.40
324.63%
Operating Profit (PBDIT) excl Other Income
-792.70
-860.10
7.84%
Interest
14.30
9.50
50.53%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-763.80
-872.20
12.43%
Operating Profit Margin (Excl OI)
-3,585.20%
-16,459.10%
1,287.39%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 324.63% vs -10.97% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 12.43% vs -48.03% in Dec 2024
About Cyfuse Biomedical KK 
Cyfuse Biomedical KK
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






